论文信息 - Long-Term P2Y12 Inhibitor or Aspirin as Single Antiplatelet Therapy in Patients With Previous Percutaneous Coronary Intervention. - 字舞流文

Long-Term P2Y12 Inhibitor or Aspirin as Single Antiplatelet Therapy in Patients With Previous Percutaneous Coronary Intervention.

D. Angiolillo | D. Capodanno

[1] R. de Caterina,et al. P2Y12 Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Network Meta-Analysis. , 2022, JACC. Cardiovascular interventions.

[2] Deepak L. Bhatt,et al. Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study , 2022, Journal of Thrombosis and Thrombolysis.

[3] Deepak L. Bhatt,et al. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention , 2022, Nature Reviews Cardiology.

[4] Theresa M. Beckie,et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2021, Journal of the American College of Cardiology.

[5] Marco Valgimigli,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. , 2019, European heart journal.

[6] David Schultz,et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.